

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report: (Date of earliest event reported): October 29, 2024

**Cibus, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-38161  
(Commission  
File Number)

27-1967997  
(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive  
San Diego, CA  
(Address of principal executive offices)

92121  
(Zip Code)

(858) 450-0008  
(Registrant's telephone number, including area code)

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Class A Common Stock, \$0.0001 par value per share	CBUS	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

Attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is an updated form of corporate presentation to be used by Cibus, Inc. in discussions with certain of its securityholders and other persons.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The information furnished in Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Cibus, Inc. Corporate Presentation October 2024</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Cibus, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 29, 2024

**CIBUS, INC.**

By: /s/ Rory Riggs  
Name: Rory Riggs  
Title: Chief Executive Officer and Chairman



CIBUS®

October 2024

CIBUS



## Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus' operational and financial performance, Cibus' strategy, future operations, prospects, and plans, including the anticipated regulatory environment are forward-looking statements. Forward-looking statements may be identified by words such as "anticipate," "believe," "intend," "expect," "plan," "scheduled," "could," "would" and "will," or the negative of these and similar expressions.

These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. Cibus' actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. The industry in which Cibus operates is emerging and subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the "Risk Factors" section of Cibus' Annual Report on Form 10-K which was filed with the Securities and Exchange Commission (the "SEC") on March 21, 2024 and other subsequent reports on Forms 10-Q and 8-K filed with the SEC. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by the Company.

In addition, the forward-looking statements included in this presentation represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.

## **Mission**

We provide traits that help farmers grow their crops more productively, economically and sustainably.

## **Technology Vision**

We use technology to accelerate development of beneficial plant traits that are indistinguishable from those evolved in nature.

# Experienced Management Team



**Rory Riggs**

CEO, Chairman  
Co-Founder

ROYALTY PHARMA  
FibroGen  
CIBUS<sup>®</sup>

Biomatrix  
Sugen  
Syntax



**Peter Beetham**

COO, President  
Co-Founder

PhD



**Greg Gocal**

EVP, Chief Scientific  
Officer, Co-founder

PhD



**Noel Sauer**

SVP,  
Head of R&D

PhD



**Carlo Broos**

SVP,  
Interim CFO

MS



**Jason Stokes**

Chief Legal Officer,  
Corporate Secretary

JD

# Cibus is a Leading Gene-Edited Agricultural Trait Company



Customers Include Major Agricultural Companies







# The Trait Business

October 2024

CIBUS® 6/16



# Traits are Fundamental to Agricultural Seed Business



# Multi-Crop and Multi-Trait Applications Leverage Trait Value

## Multi-Crop Traits

**Case Study: Bt Trait\*:**



**Cibus Example:** Sclerotinia (White Mold) Resistance in Canola and Soybean

\* The Bt trait is a third-party GMO trait. Royalties are estimated. Sources: Abqoinvestor, U.S. Government, BCG and USDA.  
 \*\* Source: U.S. Department of Agriculture, Adoption of Genetically Engineered Crops, Recent Trends in GE Crops. Canola is a company estimate.

## Stacked Traits

Traits for Non-Selective Herbicides are Industry Mainstays\*\*




In Soybean, Corn, Canola and Cotton, traits for Weed Management protecting plants from non-selective herbicides are used in > 90% of seeds sold

**Cibus Example:** Herbicide Tolerance (HT1 and HT3) in Rice

Regulations are differentiating gene-edited crops from GMO

Movement to regulate gene-edited crops as conventional varieties

EU regulatory framework has been approved and is awaiting finalization, likely effective in 2026



\* Regulatory Policy in Place means that gene edited crops are regulated as conventional varieties and not GMOs. Positive Policy Developments means ongoing research regulations are in development but no current timeline or regulatory guidance. Positive Policy Discussions Underway means the regulatory status of gene editing of crops has not been determined.  
Source: Compiled from information published directly by government authorities and industry associations including the International Seed Federation (ISF), CropLife International (CLI), and the American Seed Trade Association (ASTA). USDA FAS (USDA FAS has a comprehensive country list. See: <https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-crops-food/>)

October 2024


# Global Regulatory Environment is Advancing Favorably

CIBUS® 9/16


# Cibus' Business

October 2024

CIBUS® 10/26



# The Cibus Trait Business Model





# Cibus' 5 Trait Pipeline

## WEED MANAGEMENT

HT1 in Rice



HT2 in Canola



HT3 in Rice



- **Impact/Opportunity:** Herbicide tolerant crops provide farmers with efficient solutions to control weeds.
- **Challenge:** Farmers need to control weeds that are becoming resistant to conventional herbicides. They need better solutions.
- **Solution:** Farmers can use novel herbicides directly over the crop killing weeds and NOT the crop!
- **Status:** Cibus has completed edits and field trials to complete the product concepts.
- **Stacked-trait opportunity:** Cibus' editing technology can also stack traits to provide additional traits for tolerance to additional herbicides.

## DISEASE

### Sclerotinia in Canola



- **Impact/Opportunity:** *Sclerotinia* also known as White Mold is a major disease of Canola and Soybean and can severely affect farmer yields.
- **Challenge:** Disease control solution for farmers is to spray fungicides, often using multiple applications in a season.
- **Solution and Status:** Cibus is editing Canola targeting multiple genes to provide customer elite genetics durable tolerance

## PSR

### PSR in Canola




- **Impact/Opportunity:** Reduced yield from early seed release (pod shatter) can reduce farmers yields by 20-30%.
- **Challenge:** Not all seed companies have access to this trait.
- **Solution:** Cibus has edited multiple customer lines to date.
- **Status:** Customers elite genetics have been edited and Cibus is working with these customers to launch PSR in the next few years.

## Cibus' Advancing Soybean Platform is Aimed at Large Growing Market Opportunity

■ Brazil 2024/25: ~112 M acres  
■ US 2024/25: ~87 M acres  
**Total ~200 M acres**

Brazil and the United States total soybean harvest has grown from ~160M acres in 2015/16 to ~200M acres (est) for 2024/25



### Cibus's Advanced Traits Aimed at Highly Concentrated Soybean Market

October 2024

(\*) Cibus' anticipated Soybean Platform is Expected to be operational in 2024

(\*\*) US and Brazil Markets are estimates for the 2024-25 season.

Sources: US DA FAS.

See Appendix for Important Information, Certain Definitions, Disclaimers and End Notes

**CIBUS** 13/16



## Traits Represent a Large Potential Royalty Opportunity

Crop	Trait(s)	Principal Geographies	Target Initial Commercial Launch Date	Estimated Trait Fees per Acre per Year	Estimated Cibus Accessible Acres	Potential Total Accessible Royalties
Rice	Weed Management Traits (HT1, HT3)	U.S., Latin America	2027/2028	\$20-40	9M	\$200M
		Asia (excl. China)	2030	\$2-3	60M	\$150M
Canola	Pod Shatter Resistance	North America, EU	2026	\$5	28M	\$140M
	Weed Management (HT2)	North America, EU	2028	\$5	20M	\$100M
	Sclerotinia	North America, EU	2029	\$10	30M	\$300M
Soybean	Weed Management (HT2)	U.S., Brazil	2030	\$5	75M	\$375M
	Sclerotinia	U.S., Brazil	2031	\$10	50M	\$500M

*We expect our customers to commercially launch seeds with Cibus traits by offering them for sale to growers as early as 2026 for PSR in North America and 2027/2028 for our HT Rice traits in the Americas. Initial trait revenues are typically expected the year following commercial launch.*

**Each Trait has an Addressable Trait Fee Market > \$100M**

October 2024

(\* All estimates are management's.

See Appendix for Important Information, Certain Definitions, Disclaimers and End Notes

CIBUS

14/16

# APPENDIX - Certain Definitions and Disclaimers

## Certain Definitions

With respect to crop acres, the Company uses the terms "Accessible Acres", "Total Market" and "Customer Acres" as defined below:

"**Total Market**" or "**Total Addressable Acres**" represents the total acres planted of a specific trait crop in a specified geography, jurisdiction or market.

"**Accessible Acres**" is that portion of a specified Total Market representing management's estimate of the number of total acres for the specified geography on which seed with the specified Cibus trait may be planted. This estimate is based on industry sources or references regarding the need for a specific trait in the specific crop and geography or specific jurisdiction, taking into account assumptions about competition, trait relevance, switching costs and adoption timeframes, and various other factors. Accessible Acres may vary widely based on the trait, crop, geography or need. Among other assumptions, management includes European Union acres in determining Accessible Acres. However, access to European Union acreage is dependent upon a favorable outcome of the EU legislative process with respect to a currently pending proposal. There can be no assurance that such a favorable outcome will be achieved.

"**Customer Acres**" represents management's estimate of that portion of Accessible Acres on which Customers' seeds are planted.

"**Advanced**" with respect to traits means traits where the editing process is underway with known edit targets. With respect to a Crop Platform it means we are advanced in our plant regeneration efforts beyond the calli-stage.

"**Bt**" refers to *Bacillus thuringiensis*, a species of bacteria that lives in soil.

"**Canola**" includes Canola, Winter Oilseed Rape and Turnip Rape.

"**Commercialization**" means that the Company has delivered edited seeds back to a Customer or Customers for their commercialization purposes.

"**Crop Platform**" means, unless otherwise stated, that for the stated crop the company has an Operational or Operating plant editing system.

"**Customer**" is a party that has delivered its crop specific elite germplasm to Cibus to be edited with the goal of commercializing the specific edit in a specific crop.

"**Developed**" with respect to a trait means the trait has been validated in field trials and the Company has at least one Customer for that trait.

"**GMO**" is an acronym for "genetically modified organism" and is used by the Company to describe a transgenic plant that has been created by inserting foreign genetic material into its genome (DNA).

"**HT1**", "**HT2**" and "**HT3**" each refer to different herbicide tolerance traits.

"**Operating**" or "**Operational**" with respect to a Crop Platform means the Company can edit a single cell and regenerate the edited cell into a whole plant with the specific edit.

"**Potential Total Accessible Royalties**" represent the Company's estimates of potential annual royalties from a specific trait based on the estimated average Trait Fee per acre and the estimated Total Accessible Acres.

"**Potential Target Market Royalties**" represent management's estimate of Accessible Acres times management's estimate of the average annual Trait Fees per acre for the specific trait for a specific crop in a specific geography. The Company's estimates of Potential Target Market Royalties represents the Company's estimate of its peak sales for the specific trait and specific crop and is expected to be realized several years after initial commercial availability of seed containing the applicable trait. Actual royalties, if any, could be materially different than those expressed, implied, or anticipated by the estimates presented. Accordingly, such calculations should be considered illustrative and constitute forward-looking statements.

"**Product**" means a specific trait and regardless of crop or crops to which such trait is or may be applicable.

"**Sustainability**" refers to economic sustainability or the ability to sustain operations given costs. We equate higher yields and/or lower costs as key elements of productivity improvements and as essential elements of sustainability. We may from time to time use each of these three terms interchangeably as greater yields or greater productivity imply greater sustainability or greater sustainability is driven by higher yield or productivity.

"**Trait Fees**" represent management's assumptions regarding the potential per acre fee that Cibus may receive in respect of the applicable trait, taking into account available market information regarding competitors' current fees as well as assumptions regarding competition, trait relevance and trait value in specific geographies, and potential savings to farmers, switching costs and various other factors. Seeds containing multiple traits can result in multiple Trait Fees.

**NOTE:** Because Sclerotinia Resistance is expected to be the first commercial disease trait, there are no directly comparable Trait Fee reference points. Management estimates that the Sclerotinia Resistance Trait Fee will generally align with the relevant cost of fungicide applications, which are an alternative method to manage disease.

# APPENDIX - Certain Definitions and Disclaimers

## **Securities Law Matters**

This presentation has been prepared by Cibus, Inc. (the "Cibus" and the "Company") and the Company is responsible for its contents. It shall not constitute an offer, nor a solicitation of an offer, of the sale or purchase of any securities of the Company, nor shall any securities of the Company be offered or sold, in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

## **Intellectual Property**

The Company owns or has the right to use the trademarks, service marks, and trade names that it uses in conjunction with the operation of its business. Some of the more important marks and names that it owns or has rights to use that may appear in this presentation include: "Cibus®", "RTDS®", "Rapid Trait Development System", "Trait Machine". This presentation may also contain additional trade names, trademarks, and service marks belonging to other companies. The Company does not intend its use or display of other parties' trademarks, trade names, or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of these other parties.

## **Market Data**

Unless otherwise indicated, information contained in this presentation concerning the Company's industry and the markets in which it operates is based on information from various sources, including independent industry publications. In presenting this information, the Company has also made estimates and assumptions based on such data and other similar sources, and on its knowledge of, and its experience to date in, the potential markets for its trait products. Many, but not all, of the estimates and assumptions made by management are discussed in the Appendix included in this presentation.

